According to ROTH Capital Partners analyst Debjit Chattopadhyay, the recent market pullback has created some excellent buying opportunities in the biotech space.

During the past five years, there have been seven times that the IBB index has fallen greater than 10 percent, but it has still consistently outperformed the NASDAQ overall during that time.

Here are six biotech stocks that Chattopadhyay believes traders should be buying on the dip.

1. bluebird bio Inc BLUE 2.85%

Chattopadhyay expects continued validation for bluebird at ASH. Based on the submission deadline of August 4, outcomes from up to 14 patients could be included in the abstracts to be released in early October.

2. Cempra Inc CEMP 0.44%

Chattopadhyay believes that solithromycin is superior to moxifloxacin and argued that effective pricing strategy could position solithromycin as the first-line therapy in CAP. Chattopadhyay is looking…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!